Related Experiment Video
Updated: Jun 19, 2026

5/6 Nephrectomy Using Sharp Bipolectomy Via Midline Laparotomy in Rats
Published on: April 4, 2025
Anemia in renal disease: diagnosis and management
Christina E Lankhorst1, Jay B Wish
1Division of Nephrology, University Hospitals Case Medical Center, 11100 Euclid Ave, Cleveland, OH 44106, USA. christina.lankhorst@uhhospitals.org
Insights
Anemia is a common complication of chronic kidney disease (CKD). Treating iron deficiency and using erythropoiesis-stimulating agents (ESAs) judiciously can improve patient outcomes.
Area of Science:
- Nephrology
- Hematology
Background:
- Anemia is a frequent complication of chronic kidney disease (CKD), increasing risks for cardiovascular disease and faster renal failure.
- Causes of anemia in CKD patients are multifactorial, extending beyond erythropoietin deficiency, necessitating comprehensive evaluation.
Purpose of the Study:
- To review the management of anemia in patients with chronic kidney disease.
- To highlight the role of erythropoiesis-stimulating agents (ESAs) and iron management.
Main Methods:
- Literature review of anemia management in CKD.
- Analysis of treatment strategies including ESAs and iron supplementation.
Main Results:
- Erythropoiesis-stimulating agents (ESAs) are a primary treatment for CKD-related anemia but require careful use due to associated risks.
- Iron deficiency frequently coexists and its correction can decrease ESA needs and improve anemia.
- Partial anemia correction, not complete, is linked to better patient outcomes.
Conclusions:
- Effective management of CKD-related anemia involves addressing iron deficiency and judicious use of ESAs.
- A balanced approach to anemia correction is crucial for improving cardiovascular health and quality of life in CKD patients.
Abstract:
Chronic kidney disease (CKD) is a widespread health problem in the world and anemia is a common complication. Anemia conveys significant risk for cardiovascular disease, faster progression of renal failure and decreased quality of life. Patients with CKD can have anemia for many reasons, including but not invariably their renal insufficiency. These patients require a thorough evaluation to identify and correct causes of anemia other than erythropoietin deficiency. The mainstay of treatment of anemia secondary to CKD has become erythropoiesis-stimulating agents (ESAs). The use of ESAs does carry risks and these agents need to be used judiciously. Iron deficiency often co-exists in this population and must be evaluated and treated. Correction of iron deficiency can improve anemia and reduce ESA requirements. Partial, but not complete, correction of anemia is associated with improved outcomes in patients with CKD.
Related Concept Videos
Chronic Kidney Disease III: Interprofessional Care
Acute Kidney Injury IV: Diagnostic Studies and Prevention
Chronic Kidney Disease IV: Nursing Management
Hemodialysis III: Nursing Management
Peritoneal Dialysis III: Nursing Management
Acute Kidney Injury V: Interprofessional Care
